Amneal Pharmaceuticals Reports Q2 2026 Earnings
Amneal Pharmaceuticals (AMRX) reported second-quarter revenue of $796 million for fiscal year 2026, along with adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) of $206 million and an adjusted EPS of $0.30. The company raised its full-year outlook amid continued growth in both top-line revenue and profitability. Amneal highlighted strong performance across key segments including Affordable Medicines, biosimilars, GLP-1s, and complex generics such as transdermals and injectables. Demand for transdermal patches has increased following revised FDA guidance from the previous year, prompting Amneal to expand its production capacity. The company is also advancing a strategic acquisition of Kashiv, which would position it as a fully integrated global biosimilar player. This move aligns with an anticipated growth cycle in the U.S. biosimilars market driven by biologics losing exclusivity and streamlined regulatory pathways.
Tickers: $AMRX
Topics: financial results investor relations pharmaceuticals